PainChek (ASX:PCK) said it is compiling additional information collected from its completed clinical study to address questions from the US Food and Drug Administration, and the submission is expected to be the final step in the firm's US De Novo marketing clearance application, according to a Thursday Australian bourse filing.
The firm said the submission is expected to be the final step in the application and will be submitted before the end of June. It added that there is a commitment by the US FDA for a final decision on De Novo regulatory clearance within 75 days after receiving the submission.
It held a final feedback review meeting with the FDA, focused on addressing the regulator's final questions related to the firm's recent US clinical trial results conducted in New York and Iowa.
The firm also recruited a head of business development for the US market and established integration and reseller agreements with PointClickCare and ElderMark.
The firm's shares fell past 25% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.